Evaluation of metformin effect on progression of autosomal dominant polycystic kidney disease; a clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012102111194N1

Enrollment

Registered

2013-02-13

Start date

2013-02-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autosomal Dominant Polycystic Kidney Disease. Polycystic kidney, adult type

Interventions

Intervention 1: Tablet Metformin 500 mg three times a day. Intervention 2: Tablet placebo one tab three times a day.

Treatment - Drugs

Tablet Metformin 500 mg three times a day

Tablet placebo one tab three times a day

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion: Known case of Autosomal dominant polycystic kidney disease (by sonography); age between 18-60 years old; GFR>=60 cc/min. Exclusion: history of diabetes mellitus; history of heart failure; history of liver failure

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Kidneys volume. Timepoint: 6 months. Method of measurement: Magnetic Resonance Imaging.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Foroogh Sabzghabaei

Tehran University of Medical Science

f-sabzghabaei@tums.ac.ir+98 21 8214 1600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026